Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

AJANTA PHARMA LTD.

NSE : AJANTPHARMBSE : 532331ISIN CODE : INE031B01049Industry : Pharmaceuticals & DrugsHouse : Vimal Agrawal

BSE2786.3085.9 (+3.18 %)

PREV CLOSE ( ) 2700.40

OPEN PRICE ( ) 2707.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 14973

TODAY'S LOW / HIGH ( )2690.00 2796.80

52 WK LOW / HIGH ( )2022.05 3485.75

NSE2787.8090.1 (+3.34 %)

PREV CLOSE( ) 2697.70

OPEN PRICE ( ) 2710.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 2787.80 (101)

VOLUME 286047

TODAY'S LOW / HIGH( ) 2687.00 2794.00

52 WK LOW / HIGH ( )2223.55 3485

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 31-12 1979

Management Info

Mannalal B Agrawal - Chairman Yogesh M Agrawal - Managing Director

Registered Office

Address Ajanta House,Charkop ,Kandivali (West),
Mumbai,
Maharashtra-400067

Phone 022-60609000 / 66061000

Email legal.info@ajantapharma.com

Website www.ajantapharma.com

Registrars Details

MUFG Intime India Pvt Ltd.

C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai

Listing : BSE, NSE

NEWS

08Jul Ajanta Pharma informs about certificate
Ajanta Pharma has informed that it enclosed certificate under Regulation..

19Jun Ajanta Pharma informs about disclosure
Ajanta Pharma has informed that the exchange has received Disclosure und..

17Jun Ajanta Pharma informs about disclosure
Ajanta Pharma has informed that the exchange has received Disclosure und..

12May Ajanta Pharma informs about annual sec
Ajanta Pharma has informed that it enclosed the copy of the Annual Secre..

05May Ajanta Pharma informs about written tr
Further to communication dated 30th April 2025 on earnings call, pursuan..

Financials

Rs. in Millions

	QTR Mar 25	ANNUAL 25
Net Profit	1934.3	9168.9
Gross Profit	2281.5	11800.6
Operating Profit	2675.8	13245.9
Net Sales	10139.4	43220.4

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

SMS Lifesciences (BSE) 1299.15 (13.58%)	M.Cap ( in Cr)392.77
RPG Life Sciences (BSE) 2645.50 (3.46%)	M.Cap ( in Cr)4375.40
Gland Pharma (BSE) 1970.75 (3.94%)	M.Cap ( in Cr)32469.37
NGL Fine-Chem (BSE) 1442.05 (5.00%)	M.Cap ( in Cr)890.90
Alkem Laboratories (BSE) 5000.10 (1.35%)	M.Cap ( in Cr)59783.70

Shareholding Pattern

	PROMOTERS	66.26%
	MUTUAL FUNDS/UTI	15.13%
	NON-INSTITUTION	7.39%
	FI/BANKS/INSURANCE	1.58%
	GOVERNMENT	0.01%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
UTI Healthcare Fund...	4.92
Aditya Birla SL Pha...	3.96
NJ ELSS Tax Saver S...	3.47
PGIM India Healthca...	3.28
NJ Flexi Cap Fund-Reg(G)	3.10
Nippon India Pharma...	2.88
Kotak Healthcare Fu...	2.24

Risk Disclosures on Derivatives

Smart Quotes

AJANTA PHARMA LTD.